INTRODUCTION Reactivation of hepatitis B virus (HBV) infection in patients with past infection has been described in 5% to 10% of individuals undergoing immunosuppressive therapies. No data are available to date on the outcome of patients treated by tumour necrosis factor-alpha (TNFalpha) inhibitors for chronic arthritis with a serological pattern of past HBV infection. The aim of our study was...

BACKGROUND Occult hepatitis B infection (OBI) is a major public health problem worldwide, which harbors potential risk of hepatitis B virus (HBV) transmission through blood transfusion and transplantation. OBI is characterized by the presence of HBV-DNA in the blood or liver tissue without detectable hepatitis B surface antigen (HBsAg) in the serum. An important cause of OBI is the occurrence o...

BACKGROUND The household transmission of hepatitis B virus (HBV) is a major health problem. The prevalence rate of this infection is reported about 11% to 57% among family members of HBsAg carriers. OBJECTIVES This study was conducted to evaluate serological determinants of chronic hepatitis B infection, especially HBsAg positivity, among family members of asymptomatic HBsAg positive carriers...

Abstract Eritrea is an East African multiethnic country with intermediate endemicity for hepatitis B. Our aim was to establish the most prevalent genotypes of B virus (HBV) among patients liver disease. A total 293 Eritrean disease who were surface antigen (HBsAg) positive enrolled. All sera tested transaminases, HBV DNA viral load, and seromarkers including HBsAg, anti-HBcAb (total), HBeAg, an...

Hepatitis B virus (HBV) infection is highly endemic in Senegal. Vaccination of all children against HBV was introduced 1999 and included Expanded Programme on Immunisation 2005. The aim this study to assess the prevalence immune status patients received at Pasteur Institut Dakar, Methods: Between January 2016 December 2020, aged between 1 96 years laboratory were study. Serum samples analysed f...

Hepatitis B virus (HBV) reactivation is an increasingly recognized cause of morbidity and mortality in patients undergoing chemotherapy. In haematology, the risk of reactivation of B hepatitis among HBsAg-positive patients has been documented; therefore, use of lamivudine prophylaxis is recommended before starting chemotherapy. Differently, for HBsAg-negative patients with markers of previous H...